Selection of induction therapy in kidney transplantation (Q26864234)

main subject

kidney transplantation

1 reference

Karen L. Hardinger

1

1 reference

Daniel C. Brennan

series ordinal

2

1 reference

Christina L. Klein

series ordinal

3

1 reference

language of work or name

1 reference

July 2013

1 reference

published in

Transplant International

1 reference

volume

26

1 reference

issue

7

1 reference

page(s)

662-72

1 reference

Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation

cites work

1 reference

Rabbit antithymocyte globulin is more beneficial in standard kidney than in extended donor recipients

21 January 2018

1 reference

Five-year follow up of thymoglobulin versus ATGAM induction in adult renal transplantation

21 January 2018

1 reference

Thymoglobulin dose optimization for induction therapy in high risk kidney transplant recipients

21 January 2018

1 reference

Reduced dose rabbit anti-thymocyte globulin induction for prevention of acute rejection in high-risk kidney transplant recipients

21 January 2018

1 reference

Safety, efficacy, and cost analysis of thymoglobulin induction therapy with intermittent dosing based on CD3 lymphocyte counts in kidney and kidney-pancreas transplant recipients

21 January 2018

1 reference

Tolerogenic immunosuppression for organ transplantation

21 January 2018

1 reference

Randomized trial of single-dose versus divided-dose rabbit anti-thymocyte globulin induction in renal transplantation: an interim report

21 January 2018

1 reference

Comparison of two dosages of thymoglobulin used as a short-course for induction in kidney transplantation

21 January 2018

1 reference

Immune reconstitution following rabbit antithymocyte globulin.

21 January 2018

1 reference

Polyclonal rabbit antithymocyte globulin exhibits consistent immunosuppressive capabilities beyond cell depletion.

21 January 2018

1 reference

Interaction of antithymocyte globulins with dendritic cell antigens

21 January 2018

1 reference

Simultaneous protection against allograft rejection and graft-versus-host disease after total lymphoid irradiation: role of natural killer T cells.

21 January 2018

1 reference

A prospective, randomized, clinical trial of intraoperative versus postoperative thymoglobulin in adult cadaveric renal transplant recipients1

21 January 2018

1 reference

Analysis of infusion-site reactions in renal transplant recipients receiving peripherally administered rabbit antithymocyte globulin as compared with basiliximab

21 January 2018

1 reference

Peripheral administration of thymoglobulin for induction therapy in pancreas transplantation

21 January 2018

1 reference

Serum sickness after treatment with rabbit antithymocyte globulin in kidney transplant recipients with previous rabbit exposure

21 January 2018

1 reference

Induction therapy by anti-thymocyte globulin (rabbit) in renal transplantation: a 1-yr follow-up of safety and efficacy

21 January 2018

1 reference

Induction versus noninduction in renal transplant recipients with tacrolimus-based immunosuppression

21 January 2018

1 reference

Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study.

21 January 2018

1 reference

Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients

21 January 2018

1 reference

Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression

21 January 2018

1 reference

Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation

21 January 2018

1 reference

Cost-minimization study comparing Simulect vs. Thymoglobulin in renal transplant induction

21 January 2018

1 reference

Induction immunosuppression improves long-term graft and patient outcome in organ transplantation: an analysis of United Network for Organ Sharing registry data

21 January 2018

1 reference

Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group

21 January 2018

1 reference

Randomized double-blind study of immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantation

21 January 2018

1 reference

The impact of IL2ra induction therapy in kidney transplantation using tacrolimus- and mycophenolate-based immunosuppression

21 January 2018

1 reference

Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials

21 January 2018

1 reference

A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients

21 January 2018

1 reference

Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection

21 January 2018

1 reference

ATG versus basiliximab induction therapy in renal allograft recipients receiving a dual immunosuppressive regimen: one-year results

21 January 2018

1 reference

Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy.

21 January 2018

1 reference

Sequential protocols using basiliximab versus antithymocyte globulins in renal-transplant patients receiving mycophenolate mofetil and steroids

21 January 2018

1 reference

Rabbit antithymocyte globulin versus basiliximab in renal transplantation

21 January 2018

1 reference

A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring

21 January 2018

1 reference

Randomized trial of Alemtuzumab for prevention of graft rejection and preservation of renal function after kidney transplantation

21 January 2018

1 reference

A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation.

21 January 2018

1 reference

Alemtuzumab Induction in Renal Transplantation

21 January 2018

1 reference

Alemtuzumab induction in renal transplantation: a meta-analysis and systemic review

21 January 2018

1 reference

Multivariate analysis of antibody induction therapy and their associated outcomes in live donor kidney transplantation in the recent era

21 January 2018

1 reference

Thymoglobulin induction is safe and effective in live-donor renal transplantation: a single center experience

21 January 2018

1 reference

Clinical and economic outcomes of rabbit antithymocyte globulin induction in adults who received kidney transplants from living unrelated donors and received cyclosporine-based immunosuppression

21 January 2018

1 reference

Interleukin-2 receptor antibody reduces rejection rates and graft loss in live-donor kidney transplant recipients

21 January 2018

1 reference

Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy

21 January 2018

1 reference

Alemtuzumab versus interleukin-2 receptor antibodies induction in living donor kidney transplantation

21 January 2018

1 reference

A prospective, randomized, multicenter study evaluating early corticosteroid withdrawal with Thymoglobulin in living-donor kidney transplantation

21 January 2018

1 reference

Delayed graft function in renal transplantation: etiology, management and long-term significance

21 January 2018

1 reference

Efficacy of induction therapy on acute rejection and graft outcomes in African American kidney transplantation

21 January 2018

1 reference

Induction therapy with basiliximab versus Thymoglobulin in African-American kidney transplant recipients

21 January 2018

1 reference

Influence of race on kidney transplantation in the Department of Defense healthcare system

21 January 2018

1 reference

Outcomes in African-Americans vs. Caucasians using thymoglobulin or interleukin-2 receptor inhibitor induction: analysis of USRDS database

21 January 2018

1 reference

Interleukin-2 receptor antagonist does not decrease biopsy-proven acute rejection among adult Chinese kidney transplant recipients

21 January 2018

1 reference

A prospective randomized trial of steroid-free maintenance regimens in kidney transplant recipients--an interim analysis

21 January 2018

1 reference

Randomized prospective trial of early steroid withdrawal compared with low-dose steroids in renal transplant recipients using serial protocol biopsies to assess efficacy and safety

21 January 2018

1 reference

Induction antibody therapy in renal transplantation using early steroid withdrawal: long-term results comparing anti-IL2 receptor and anti-thymocyte globulin.

21 January 2018

1 reference

Multivariate analysis of risk factors for acute rejection in early corticosteroid cessation regimens under modern immunosuppression

21 January 2018

1 reference

Induction Immunosuppressive Therapy in the Elderly Kidney Transplant Recipient in the United States

21 January 2018

1 reference

Mycophenolate mofetil in pediatric renal transplantation: non-induction vs. induction with basiliximab

21 January 2018

1 reference

Infectious Complications Associated with Alemtuzumab Use for Lymphoproliferative Disorders

21 January 2018

1 reference

Opportunistic Infections in 547 Organ Transplant Recipients Receiving Alemtuzumab, a Humanized Monoclonal CD-52 Antibody

21 January 2018

1 reference

Basiliximab induction therapy for live donor kidney transplantation: a long-term follow-up of prospective randomized controlled study

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/TRI.12043

0 references

PubMed publication ID

23279211

1 reference